Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 2089, United States of America; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, PR China.
Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 2089, United States of America; Department of Biochemistry and Molecular and Cellular Biology, Georgetown University, Washington, DC, United States of America.
Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Oct;1864(10):1396-1411. doi: 10.1016/j.bbalip.2019.05.014. Epub 2019 Jun 10.
Peroxisome proliferator-activated receptor alpha (PPARα) controls lipid homeostasis through regulation of lipid transport and catabolism. PPARα activators are clinically used for hyperlipidemia treatment. The role of PPARα in bile acid (BA) homeostasis is beginning to emerge. Herein, Ppara-null and hepatocyte-specific Ppara-null (Ppara) as well as the respective wild-type mice were treated with the potent PPARα agonist Wy-14,643 (Wy) and global metabolomics performed to clarify the role of hepatocyte PPARα in the regulation of BA homeostasis. Levels of all serum BAs were markedly elevated in Wy-treated wild-type mice but not in Ppara-null and Ppara mice. Gene expression analysis showed that PPARα activation (1) down-regulated the expression of sodium-taurocholate acid transporting polypeptide and organic ion transporting polypeptide 1 and 4, responsible for the uptake of BAs into the liver; (2) decreased the expression of bile salt export pump transporting BA from hepatocytes into the bile canaliculus; (3) upregulated the expression of multidrug resistance-associated protein 3 and 4 transporting BA from hepatocytes into the portal vein. Moreover, there was a notable increase in the compositions of serum, hepatic and biliary cholic acid and taurocholic acid following Wy treatment, which correlated with the upregulated expression of the Cyp8b1 gene encoding sterol 12α-hydroxylase. The effects of Wy were identical between the Ppara and Ppara-null mice. Hepatocyte PPARα controlled BA synthesis and transport not only via direct transcriptional regulation but also via crosstalk with hepatic farnesoid X receptor signaling. These findings underscore a key role for hepatocyte PPARα in the control of BA homeostasis.
过氧化物酶体增殖物激活受体α(PPARα)通过调节脂质转运和分解代谢来控制脂质稳态。PPARα 激动剂临床上用于治疗高脂血症。PPARα 在胆汁酸(BA)稳态中的作用开始显现。本文中,我们使用强效 PPARα 激动剂 Wy-14,643(Wy)处理 Ppara 敲除和肝特异性 Ppara 敲除(Ppara)以及相应的野生型小鼠,进行了全局代谢组学分析,以阐明肝 PPARα 在调节 BA 稳态中的作用。Wy 处理的野生型小鼠血清中所有 BA 的水平显着升高,但 Ppara 敲除和 Ppara 小鼠则没有。基因表达分析表明,PPARα 激活(1)下调了负责 BA 摄取到肝脏的牛磺胆酸钠转运多肽和有机阴离子转运多肽 1 和 4 的表达;(2)降低了将 BA 从肝细胞分泌到胆小管的胆汁盐输出泵的表达;(3)上调了将 BA 从肝细胞转运到门静脉的多药耐药相关蛋白 3 和 4 的表达。此外,Wy 处理后血清、肝和胆汁中的胆酸和牛磺胆酸组成明显增加,这与编码甾醇 12α-羟化酶的 Cyp8b1 基因的上调表达相关。Wy 的作用在 Ppara 和 Ppara 敲除小鼠之间是相同的。肝 PPARα 通过直接转录调节以及与肝法尼醇 X 受体信号的串扰来控制 BA 的合成和转运。这些发现强调了肝 PPARα 在控制 BA 稳态中的关键作用。